Separately, Sinovac released details on Monday from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects. CoronaVac is already undergoing a late-stage trial in Brazil and Sinovac expects to also test it in Bangladesh. In addition to Bio Farma and Sinovac, private Indonesian firm Kalbe Farma and South Korea's Genexine are cooperating to produce a separate vaccine. Vaccines used in the late-stage trials will be made using the optimised process, a Sinovac spokesman said. Sinovac is testing its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.

Source: bd News24 August 11, 2020 07:30 UTC